AzTrials
AzTrials

Coronary StenosisNCT03702764

Coronary Plaque Geometry and Acute Coronary Syndromes

An observational study of Coronary Stenosis and Acute Coronary Syndrome, run by Cardio Med Medical Center at 1 site in Romania.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The aim of GEOMETRY study is to investigate the correlation between coronary plaque geometric modifications and lesion vulnerability in patients with suspected coronary artery disease referred for cardiac computed tomography angiography (CCTA). Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
CCTA
How many people
1,000 participants
Where
1 siteRomania
Study dates
1 Feb 2019to 30 Nov 2021
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Adult, Older adult

Study population: Study population includes patients from a single center with suspected coronary artery disease, meeting inclusion and exclusion criteria and undergoing CCTA by physician referral for coronary luminal evaluation.

Who may be able to join

  • Patients with suspected coronary artery disease (CAD) and pre-test probability of CAD between 15% and 85%, who undergo CCTA, and in whom CCTA has identified presence of at least one coronary plaque
  • Ability to provide informed consent
  • Age grater then 18 years

Who cannot join

  • Patients with pre-test probability of CAD >85% or <15%
  • Electrocardiographic evidence of STEMI
  • Presence of pre-existing CAD including prior myocardial infarction
  • History of coronary artery revascularization (by percutaneous coronary intervention, stent or bypass graft surgery)
  • Atrial fibrillation or other irregular rhythm
  • Unwillingness or incapacity to provide informed consent
Show all 13Show fewer
  • Allergy to iodine contrast media
  • Inability to tolerate beta-blocker medication
  • Renal insufficiency (creatinine greater than 1.5 mg/dL) or renal failure requiring dialysis
  • Pregnant women or lactation
  • Active malignancy or malignancy within the last 5 year prior to enrolment
  • Conditions associated with an estimated life expectancy of under 2 years
  • Coronary calcium score >1000

Trial locations and contacts

1 site in 1 country.

Romania1 site
  • Cardio Med Medical Center

    Târgu Mureş, Mureș County, 540102

Other trials in Romania

About this study

Official title: Definition: Impact of Coronary Plaque Geometry on Plaque Vulnerability and Their Association With the Risk of Future Cardiovascular Events in Patients With Chest Pain Undergoing Coronary Computed Tomographic Angiography - the GEOMETRY STUDY

The aim of GEOMETRY study is to investigate the correlation between coronary plaque geometric modifications and lesion vulnerability in patients with suspected coronary artery disease referred for cardiac computed tomography angiography (CCTA). Furthermore the study will evaluate the impact of plaque eccentricity and morphology on the rate of major adverse cardiovascular events (MACE) for a 2 years follow-up period.

Read the detailed description

Coronary artery disease (CAD) remains the leading cause of mortality and morbidity worldwide. Early detection of CAD may reduce the incidence of myocardial infarction by improving primary prevention and providing more effective treatment methods. A step in this direction is identifying the pattern of coronary plaques which are prone to rupture. Coronary computed tomography angiography (CCTA) has emerged recently as a reliable noninvasive tool used in the evaluation of coronary arteries. Some features related to plaque composition and morphology such as low attenuation plaques, spotty calcification, positive remodeling or napkin ring sign, were already identified as vulnerability markers. However the role of lesion geometry on plaque vulnerability was not investigated yet.

This is a prospective, cohort, single-center study which will be carried out in the Center of Advanced Research in Multimodal Cardiac Imaging Cardiomed.

The study will include 1.000 subjects with suspected CAD who are referred to CCTA by the attending physician and in which presence of at least one coronary plaque is confirmed by CCTA.

Plaque burden, composition, and morphology will be assessed for each plaque. Longitudinal and transversal eccentricity will be also assessed in each plaque and in all cases, eccentricity index will be calculated in cross-section plane at the degree of maximum stenosis in order to determine the position of the remaining circulant lumen and to classify the plaque into concentric and eccentric lesion.

The study will be conducted over a period of 3 years, in which patients will be examined at baseline, and will be followed-up for 2 years for occurrence of MACE.

Study objectives:

Primary: to evaluate the association between different patterns of plaque geometry and the risk for major adverse cardiac events MACE (all-cause mortality, cardiovascular death, myocardial infarction, repeated revascularization, repeated hospitalizations for cardiovascular related incidents, cerebrovascular events) during a 2-year follow-up, Secondary: to evaluate the association of plaque eccentricity, plaque vulnerability and plaque progression after 2 years of follow-up

Study Timeline:

  • Baseline (day 0)
  • Obtain and document consent from participant on study consent form.
  • Verify inclusion/exclusion criteria.
  • Obtain demographic information, medical history, medication history, alcohol and tobacco use history.
  • Record results of physical examinations and 12-lead ECG.
  • Collect blood specimens.
  • Imaging: 128-multislice CT angiography.
  • Visit 1 (month 6)
  • Record results of physical examinations, 12-lead ECG and medical history.
  • MACE assessment
  • Visit 2 (month 12)
  • Record results of physical examinations, 12-lead ECG and medical history.
  • MACE assessment
  • Visit 3 (month 18)
  • Record results of physical examinations, 12-lead ECG and medical history.
  • MACE assessment
  • Final study visit (month 24)
  • Record results of physical examinations, 12-lead ECG and medical history.
  • Repeat CCTA and plaque assessment
  • End-point evaluation.

Study procedures:

  • Medical history, clinical examination, laboratory tests;
  • 12-lead ECG
  • 128-multislice CT coronary angiography with the evaluation of: calcium score, plaque burden, markers for lesion severity (degree of stenosis, lesion length, lumen area and diameter, minimum and maximum plaque thickness); morphological plaque characteristics (plaque related volumes, plaque burden, remodeling indexes); shear stress by computational fluid dynamics; markers of plaque vulnerability (low attenuation plaque, spotty calcification, positive remodeling, napkin ring sign); plaque geometry by eccentricity index, longitudinal and transversal eccentricity.
Being tested
CCTA
Keywords
coronary plaque eccentricity, vulnerable coronary plaque, coronary artery disease, myocardial infarction, coronary computed tomography angiography, major adverse cardiac events
Medical subject headings
Coronary Stenosis, Acute Coronary Syndrome, Atherosclerosis, Plaque, Atherosclerotic, Coronary Artery Disease, Myocardial Infarction, Cardiovascular Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CCTADiagnostic test

    128-multislice CT coronary angiography and complex atherosclerotic plaque analysis, with the use of CT imaging post-processing techniques.

Study groups in NCT03702764
Study groupRoleWhat they receive
VP-SG 01Study subjects that present concentric coronary plaques
Receives: Diagnostic Test: CCTA
VP-SG 02Study subjects that present eccentric coronary plaques
Receives: Diagnostic Test: CCTA

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Major adverse cardiovascular events

    Incidence of MACE during follow-up

    Measured: Month 24

Secondary outcomes (1)
  1. Coronary plaque vulnerability associated to plaque eccentricity

    Number of vulnerability markers in eccentric vs concentric plaques

    Measured: Month 24

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Oct 2018
  2. Study start1 Feb 2019
  3. Primary completion30 Nov 2019
  4. Study completion30 Nov 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
1,000 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03702764
Sponsor's protocol ID
CM0218-GEO
Status last verified
Jul 2021
First submitted
8 Oct 2018
Last updated
2 Aug 2022
Results posted
No

Questions about this trial

What is this clinical trial studying?

An observational study of Coronary Stenosis and Acute Coronary Syndrome, run by Cardio Med Medical Center at 1 site in Romania.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 2 Aug 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Romania. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Major adverse cardiovascular events (time frame: Month 24). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Aug 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in